Flucelvax® Quadrivalent Influenza Vaccine, 2019/2020 Season (0.5 mL Syringe)

Catalog No. NR-53880
This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:
Melissa Ma, Fisher BioServices, Germantown, Maryland, USA
and National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:
Seqirus, Inc., Holly Springs, North Carolina, USA

Product Description:
NR-53880 is a subunit influenza virus vaccine prepared from virus propagated in Madin-Darby canine kidney (MDCK) cells. The virus was inactivated with β-propiolactone, disrupted by the detergent cetyltrimethylammonium bromide and purified through several process steps. Each of the four virus strains were produced and purified separately and then pooled to formulate the quadrivalent vaccine.

The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended ratio of 15 µg each of the hemagglutinin (HA) antigens from influenza viruses A/Idaho/07/2018 [an A/Brisbane/02/2018 (H1N1)pdm09-like virus], A/Indiana/08/2018 [an A/Kansas/14/2017 (H3N2)-like virus], B/Iowa/06/2017 (a B/Colorado/06/2017-like virus) and B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus). Flucelvax Quadrivalent 0.5 mL pre-filled vaccine syringes contain no preservatives or antibiotics.

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2019-2020 season are now past their expiration dates. (Expires: JUN2020)

Material Provided:
Each syringe contains 0.5 mL of virus suspension in phosphate-buffered saline.

Packaging/Storage:
NR-53880 is packaged in a 0.5 mL prefilled syringe. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze. Protect from light.

Citation:
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Flucelvax® Quadrivalent Influenza Vaccine, 2019/2020 Season (0.5 mL Syringe), NR-53880.”

Biosafety Level: 1

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

ATCC® is a trademark of the American Type Culture Collection.